Can infliximab serve as a new therapy for neuropsychiatric symptoms?

Neuropsychiatric disorders present a global challenge to public health. Mechanisms associated with neuropsychiatric disorders etiology include apoptosis, oxidative stress, and neuroinflammation. Tumor necrosis factor alpha, an inflammatory cytokine, mediates pathophysiology of neuropsychiatric disor...

Full description

Saved in:
Bibliographic Details
Published in:Naunyn-Schmiedeberg's archives of pharmacology 2024-09
Main Authors: Rahmati-Dehkordi, Fatemeh, Birang, Nafiseh, Jalalian, Mohammad Naser, Tamtaji, Zeinab, Dadgostar, Ehsan, Aschner, Michael, Shafiee Ardestani, Mehdi, Jafarpour, Hamed, Mirzaei, Hamed, Nabavizadeh, Fatemeh, Tamtaji, Omid Reza
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neuropsychiatric disorders present a global challenge to public health. Mechanisms associated with neuropsychiatric disorders etiology include apoptosis, oxidative stress, and neuroinflammation. Tumor necrosis factor alpha, an inflammatory cytokine, mediates pathophysiology of neuropsychiatric disorders. Therefore, its inhibition by infliximab might afford a valuable target for intervention. Infliximab is commonly used to treat inflammatory diseases, including ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Recently, it has been shown that infliximab improves cognitive dysfunction, depression, anxiety, and life quality. Here, we review contemporary knowledge supporting the need to further characterize infliximab as a potential treatment for neuropsychiatric disorders.
ISSN:0028-1298
1432-1912
1432-1912
DOI:10.1007/s00210-024-03397-w